FAIRFIELD, Conn., May 24, 2010 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) today announced the issuance of an abstract of a study which has shown the successful treatment of Chronic Cancer Pain (CCP) using CTT's Calmare® Pain Therapy Treatment for patients with advanced stages of cancer. The abstract cites results of the study, which will be published in the proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 4-8, 2010. Also at this meeting, the results of a previously announced study showing successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using Calmare pain therapy will be presented.
Calmare, which treats chronic neuropathic and oncologic pain, received FDA certification for sales in the U.S. in February 2009, and CE Certification sales in Europe in June of 2008. Clinical investigators from the I.R.S.T. in Meldola, Italy, and Palliative Care Unit at Forli, Italy, conducted an independent clinical study to specifically examine the ability of CTT's Calmare pain therapy treatment to decrease chronic pain associated with cancer – CCP – which is present in approximately 50 percent of all cancer patients and up to 70 percent of those with advanced stages of cancer.
"I am so honored and pleased that our technology is helpful to relieve the pain of millions of patients, especially patients suffering with cancer," said Professor Giuseppe Marineo, who developed the biophysical "Scrambler Therapy" technology, which is used in the non-invasive Calmare pain therapy device, in Italy. "With treatment protocol experience, the quality of results with 'Scrambler Therapy' and successful outcomes achieved are expected to exceed 90%. The psychological reward is very gratifying."
"The results of this study from Italy add to the growing body of evidence that shows our Calmare pain therapy device successfully treats the various types of neuropathic pain suffered by millions of cancer patients. Calmare pain therapy effectively treats CCP and is the only highly effective treatment for CIPN without harmful, adverse side effects," said John B. Nano, CTT's Chairman, President and CEO. "Finding new, non-invasive ways to treat pain other than prescribing opioids such as morphine is a key focus of our mission to improve the quality of life for cancer patients. We expect to create a paradigm shift in how chronic pain is treated globally, including for the 75 million Americans who suffer from chronic pain."
The abstract highlights the results of a 16-month study in which patients with CCP were treated with the Calmare device. At the end of the second week of a two-week treatment protocol, " … Therapy was considered satisfactory by 63% of patients. … Our preliminary results indicate the potential effectiveness of Scrambler [Calmare] therapy for pain control in patients with advanced cancer." The abstract is available at: http://abstract.asco.org/AbstView_74_50422.html.
Calmare is being used to treat international patients in Italy, India, Greece, Bangladesh, and U.S. patients at clinics in Massachusetts, New York, Virginia, Florida, Connecticut and Rhode Island. In addition to treating pain associated with cancer and cancer treatments, the Calmare device also successfully treats chronic neuropathic pain resulting from shingles, failed back surgery, phantom limb syndrome, sciatica, spinal stenosis and other maladies.
CTT's partner, GEOMC Co. Ltd. of Seoul, Korea, is currently manufacturing the Calmare device for sale. For more information on the device, visit www.calmarett.com.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.